Rockville, Md. -- FDA has agreed to extend the comment period on a final rule prohibiting use of cephalosporin antibiotics in food-producing animals. The new deadline is Nov. 1, 2008.
Rockville, Md.
-- The Food and Drug Administration (FDA) is extending the comment period (Nov. 1) on a final rule calling for the prohibition of extra-label use of cephalosporin in food-producing animals. The FDA is also delaying the effective date of this final rule to Nov. 30.
The agency received extension requests from various groups citing a need for additional time to examine available evidence, consider the ruling's potential impact, and provide constructive comment.
"After careful consideration, the agency believes that a 60-day extension allows adequate time for interested persons to submit comments without significantly delaying implementation of the final rule, " the agency reported today.
The order prohibiting the extra-label use of cephalosporin antimicrobial drugs in food-producing animals was originally announced in the Federal Register on July 3, 2008, with a 60-day comment period and a 90-day effective date for the final rule.
FDA approves oral drug for broad canine protection against parasites
October 7th 2024Elanco's lotilaner, moxidectin, praziquantel, and pyrantel chewable tablets (Credelio Quattro) provide a single monthly dose for protection against fleas, ticks, heartworms, roundworms, hookworms, and 3 species of tapeworm.
Read More
Podcast CE: A Surgeon’s Perspective on Current Trends for the Management of Osteoarthritis, Part 1
May 17th 2024David L. Dycus, DVM, MS, CCRP, DACVS joins Adam Christman, DVM, MBA, to discuss a proactive approach to the diagnosis of osteoarthritis and the best tools for general practice.
Listen
dvm360 announces winners of the Veterinary Heroes program
Published: September 6th 2024 | Updated: November 5th 2024This year’s event is supported by corporate sponsor Schwarzman Animal Medical Center and category sponsors Blue Buffalo Natural, MedVet, Banfield Pet Hospital, Thrive Pet Healthcare and PRN Pharmacal.
Read More